Profitability
Weight: 20%
F
16
- 5yr Avg ROIC -15.0%
- Operating Margin Trend +0.00 pp/yr
VERA
Vera Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 23.8 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -22.1%
- 5yr Share-Count CAGR 47.9%
Growth Quality
Weight: 15%
F
16
- 5yr Revenue CAGR 0.0%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 0/5
Cash Generation
Weight: 15%
F
14
- 5yr FCF Margin 0.0%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
F
25
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -38.78x
- Altman Z-Score 9.20
Stability
Weight: 15%
B
73
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 1
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 new buy; 1 trimmed.
- Holders
- 2 +1
- Avg Δ position
- -99.5%
- New buys
- 1
- Full exits
- 0